UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-------------------------------------------------------------------------------------|------------------------------------------| | | | | For the transition period from _______ ...

Company Overview - Aura Biosciences is developing virus-like drug conjugates (VDCs) to target multiple solid tumor indications, including ocular and bladder cancers[6] - The company highlights a multi-billion-dollar addressable market opportunity with its novel platform to treat multiple solid tumors[6] - Aura Biosciences has a strong cash position with a cash runway to fund operations into 2025[6] Ocular Oncology Program - The company initiated activities for a global Phase 3 trial for Primary Choroidal Melanoma and plans to initiate a Phase 2 trial for Choroidal Metastasis in the second half of 2023[6] - In Primary Choroidal Melanoma, approximately 80% of patients are diagnosed with early-stage disease, representing a significant target population[17] - Current radiotherapy treatments leave approximately 70% of patients with major irreversible vision loss within 5-10 years[26] - Phase 2 interim data showed an 89% tumor control rate in the highest dose/regimen group (3 cycles)[39] and 100% tumor control rate in planned Phase 3 population[46] - Phase 2 interim analysis demonstrated visual acuity preservation in approximately 90% of patients[47] - Phase 2 interim data demonstrated a statistically significant tumor growth rate reduction with a p-value of <0.0001 in the planned Phase 3 population[53] - The company estimates a total addressable market of 33,500 for the Ocular Oncology Franchise, including 20,000 Choroidal Metastasis patients diagnosed each year in the US/EU[70, 71] Urologic Oncology Program - The company is enrolling patients in a Phase 1 trial in Non-Muscle Invasive Bladder Cancer (NMIBC), with initial data expected in the second half of 2023[84] - The company notes that NMIBC has a high incidence globally, affecting over 500,000 patients per year[84]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40971 AURA BIOSCIENCES, INC. (Exact name of Registrant as specified in its Charter) Delaware 32-0271970 (State or other jurisdiction ...

PART I. [FINANCIAL INFORMATION](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=6&type=section&id=Item%201.%20Financial%20Statements) Aura Biosciences' unaudited consolidated financial statements as of September 30, 2022, present key financial positions, operations, and cash flows Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | September 30, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $61,110 | $149,063 | | Marketable securities | $50,409 | $0 | | **Total Assets** | **$143,147** | **$160,030** | | Total current liabilities | $9,964 | $7,355 | | Long-term operating lease liability | $18,129 | $360 | | **Total Liabilities** | **$28,093** | **$7,715** | | **Total Stockholders' Equity** | **$115,054** | **$152,315** | Condensed Consolidated Statements of Operations Highlights (in thousands) | Metric | Nine Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2021 | | :--- | :--- | :--- | | Research and development | $29,079 | $17,182 | | General and administrative | $13,603 | $6,441 | | **Total operating loss** | **($42,682)** | **($23,623)** | | **Net loss** | **($42,204)** | **($23,617)** | | **Net loss per share** | **($1.44)** | **($77.93)** | Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Nine Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | ($36,588) | ($20,324) | | Net cash used in investing activities | ($50,993) | ($1,306) | | Net cash provided by financing activities | $430 | $86,117 | - As of the report issuance date, the company expects its cash, cash equivalents, and marketable securities of **$111.5 million** to be sufficient to fund operating expenses and capital requirements through at least the next 12 months[28](index=28&type=chunk)[30](index=30&type=chunk) - On November 1, 2022, the company filed a shelf registration statement for up to **$250.0 million** and entered into an "at-the-market" (ATM) offering agreement for up to **$75.0 million** of its common stock[102](index=102&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses financial condition, operational results, and belzupacap sarotalocan's clinical progress, highlighting expenses and liquidity [Overview](index=22&type=section&id=MD%26A%20Overview) Aura Biosciences, a clinical-stage biotech, advances belzupacap sarotalocan for ocular and urologic cancers, planning a global Phase 3 trial - The lead product candidate, belzupacap sarotalocan, has received **Orphan Drug Designation** and **Fast Track Designation** from the FDA for the treatment of uveal melanoma[106](index=106&type=chunk) - Interim six-month data from the Phase 2 trial of belzupacap sarotalocan with suprachoroidal (SC) administration showed a favorable safety profile, high levels of visual acuity preservation, and a statistically significant tumor growth rate reduction (**p = 0.0007**)[106](index=106&type=chunk) - The company is expanding into urologic oncology, having initiated a **Phase 1 trial** for non-muscle invasive bladder cancer (NMIBC) in September 2022, with initial data expected in 2023[107](index=107&type=chunk) [Results of Operations](index=26&type=section&id=MD%26A%20Results%20of%20Operations) This section compares Q3 and nine-month operating results, highlighting increased net losses due to higher R&D and G&A expenses Comparison of Operating Results (in thousands) | Period | R&D Expense | G&A Expense | Net Loss | | :--- | :--- | :--- | :--- | | **Q3 2022** | $11,293 | $4,762 | ($15,901) | | **Q3 2021** | $6,365 | $2,530 | ($8,838) | | **Nine Months 2022** | $29,079 | $13,603 | ($42,204) | | **Nine Months 2021** | $17,182 | $6,441 | ($23,617) | - The increase in R&D expenses was primarily due to ongoing preclinical costs, manufacturing and development costs for belzupacap sarotalocan, and higher personnel expenses from growing headcount[132](index=132&type=chunk)[138](index=138&type=chunk) - The increase in G&A expenses was driven by higher personnel costs and increased general corporate expenses related to operating as a public company[133](index=133&type=chunk)[139](index=139&type=chunk) [Liquidity and Capital Resources](index=27&type=section&id=MD%26A%20Liquidity%20and%20Capital%20Resources) Liquidity from equity sales, with **$111.5 million** cash as of September 30, 2022, funds operations into 2024, but substantial additional capital is needed - As of September 30, 2022, the company had cash, cash equivalents, and marketable securities totaling **$111.5 million**[114](index=114&type=chunk)[150](index=150&type=chunk) - The company believes its existing cash will be sufficient to fund operating expenses and capital expenditure requirements into **2024**, but this will not be enough to fund belzupacap sarotalocan through regulatory approval[150](index=150&type=chunk)[177](index=177&type=chunk) Material Cash Requirements (in thousands) | Commitment | Total | Less than 1 Year | 1 to 3 Years | 3 to 5 Years | More than 5 Years | | :--- | :--- | :--- | :--- | :--- | :--- | | Operating lease commitments | $34,718 | $3,089 | $6,458 | $6,851 | $18,320 | [Quantitative and Qualitative Disclosures About Market Risk](index=30&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) As a smaller reporting company, Aura Biosciences is not required to provide quantitative and qualitative disclosures about market risk - The company is a **smaller reporting company** as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item[161](index=161&type=chunk) [Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management, including CEO and CFO, concluded disclosure controls were effective as of September 30, 2022, with no material internal control changes - Management, including the CEO and CFO, concluded that as of September 30, 2022, the company's disclosure controls and procedures were effective[164](index=164&type=chunk) - No change in internal control over financial reporting occurred during the quarter that has materially affected, or is reasonably likely to materially affect, internal controls[165](index=165&type=chunk) PART II. [OTHER INFORMATION](index=32&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=32&type=section&id=Item%201.%20Legal%20Proceedings.) As of September 30, 2022, the company is not party to any claim or litigation expected to have a material adverse effect on its business - As of September 30, 2022, the company does not believe it is party to any claim or litigation that would be reasonably expected to have a material adverse effect on its business[167](index=167&type=chunk) [Risk Factors](index=32&type=section&id=Item%201A.%20Risk%20Factors.) This section outlines material risks related to financial position, product development, third-party reliance, commercialization, intellectual property, and general business [Risks Related to Financial Position and Capital Needs](index=32&type=section&id=Risks%20Related%20to%20Our%20Financial%20Position%2C%20and%20Additional%20Capital%20Needs) This section details financial risks, including significant net losses, an accumulated deficit of **$194.3 million**, and the need for substantial additional capital - The company has incurred significant net losses since inception, with an accumulated deficit of **$194.3 million** as of September 30, 2022, and expects to incur increasing operating losses for the foreseeable future[170](index=170&type=chunk) - Substantial additional capital is required to finance operations. Existing cash is expected to fund operations into **2024** but is not sufficient to complete the development and commercialization of belzupacap sarotalocan[176](index=176&type=chunk)[177](index=177&type=chunk) [Risks Related to the Discovery and Development of our Product Candidates](index=36&type=section&id=Risks%20Related%20to%20the%20Discovery%20and%20Development%20of%20our%20Product%20Candidates) This section outlines product development risks, including dependence on belzupacap sarotalocan, regulatory uncertainty for combination products, and clinical trial failures - The company's business is heavily dependent on the successful development, regulatory approval, and commercialization of its only product candidate, **belzupacap sarotalocan**[190](index=190&type=chunk) - The company has not yet successfully initiated or completed any pivotal clinical trials or commercialized any products, making it difficult to evaluate future prospects[200](index=200&type=chunk) - Belzupacap sarotalocan is a **biologic-device combination product**, which may result in additional regulatory complexity and risks during the approval process[204](index=204&type=chunk) [Risks Related to Our Reliance on Third Parties](index=47&type=section&id=Risks%20Related%20to%20Our%20Reliance%20on%20Third%20Parties) This section details risks from reliance on third parties for clinical trials and manufacturing, including performance, compliance, and single-source supply disruptions - The company relies on third parties like **CROs** to conduct clinical trials, which reduces direct control over these activities but does not relieve the company of its regulatory responsibilities[247](index=247&type=chunk)[248](index=248&type=chunk) - The company relies on third-party **CMOs** for the manufacture of belzupacap sarotalocan and is currently reliant on a **single source** for each of its regulatory starting materials, drug substance, and drug product[252](index=252&type=chunk) [Risks Related to Commercialization](index=50&type=section&id=Risks%20Related%20to%20Commercialization) This section covers commercialization risks, including market acceptance, lack of sales infrastructure, intense competition, uncertain pricing, and healthcare law compliance - The company currently has no sales, marketing, or distribution capabilities and no experience in marketing products, which will require significant investment and resources to build[266](index=266&type=chunk) - The market opportunity for belzupacap sarotalocan may be smaller than estimated, which would adversely affect potential revenue and profitability[277](index=277&type=chunk) - The business is subject to numerous healthcare laws and regulations (e.g., **Anti-Kickback Statute**, **False Claims Act**, **HIPAA**), and non-compliance could lead to significant penalties[279](index=279&type=chunk)[281](index=281&type=chunk) [Risks Related to Intellectual Property](index=58&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) This section details intellectual property risks, including patent protection challenges, reliance on third-party licenses, and the difficulty of protecting trade secrets - The company's ability to compete depends on adequately protecting its proprietary rights, which is subject to challenges, potential invalidation, and the high cost of enforcement[299](index=299&type=chunk)[301](index=301&type=chunk) - The company relies on intellectual property licensed from third parties and could lose these rights if it fails to comply with its obligations under the license agreements[307](index=307&type=chunk) - The company relies on confidentiality agreements to protect trade secrets, such as the manufacturing process for the **IRDye 700DX® dye** used in its lead product, which may be breached or difficult to enforce[327](index=327&type=chunk) [General Risks](index=63&type=section&id=General%20Risks) This section outlines general business risks, including personnel, disruptions, cybersecurity, data privacy, stock volatility, dilution, ownership, and emerging growth company status - The company's executive officers, directors, and 5%+ stockholders beneficially own approximately **60.1%** of its outstanding common stock, enabling them to exert significant influence over corporate actions[378](index=378&type=chunk) - The company is an "**emerging growth company**" and a "**smaller reporting company**," which allows for reduced public reporting requirements but may make its stock less attractive to some investors[402](index=402&type=chunk) - Future sales of common stock, including through a new "**at-the-market**" (ATM) program, will be necessary for additional capital but could result in significant dilution to existing stockholders and cause the stock price to decline[393](index=393&type=chunk)[394](index=394&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=80&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds.) No unregistered equity sales occurred, and no material change in the planned use of **$78.3 million** net IPO proceeds from November 2021 - The company completed its IPO on November 2, 2021, receiving total net proceeds of approximately **$78.3 million** after the underwriters fully exercised their option[420](index=420&type=chunk) - There has been no material change in the planned use of proceeds from the IPO as disclosed in the original prospectus[422](index=422&type=chunk) [Defaults Upon Senior Securities](index=80&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities.) This item is not applicable to the company for the reporting period - Not applicable[422](index=422&type=chunk) [Mine Safety Disclosures](index=80&type=section&id=Item%204.%20Mine%20Safety%20Disclosures.) This item is not applicable to the company for the reporting period - Not applicable[422](index=422&type=chunk) [Other Information](index=80&type=section&id=Item%205.%20Other%20Information.) The company reported no other information for this item during the period - None[422](index=422&type=chunk) [Exhibits](index=81&type=section&id=Item%206.%20Exhibits.) This section lists exhibits filed with the Form 10-Q, including corporate documents and certifications from the Principal Executive and Financial Officers - The filing includes certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Sections **302** and **906** of the Sarbanes-Oxley Act of 2002[425](index=425&type=chunk)

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents unaudited condensed consolidated financial statements for Q1 2022, showing a $12.8 million net loss and increased operating expenses [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2022, total assets were $146.4 million, down from $160.0 million, primarily due to reduced cash and cash equivalents Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $108,382 | $149,063 | | Marketable securities | $24,899 | $0 | | **Total Assets** | **$146,422** | **$160,030** | | Total Liabilities | $7,715 | $5,336 | | **Total Stockholders' Equity** | **$141,086** | **$152,315** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For Q1 2022, the company reported a $12.8 million net loss, a significant increase from $5.9 million in Q1 2021, driven by higher R&D and G&A expenses Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | Research and development | $8,276 | $4,185 | | General and administrative | $4,535 | $1,742 | | **Total operating expenses** | **$12,811** | **$5,927** | | **Net loss** | **$(12,835)** | **$(5,927)** | | Net loss per share | $(0.44) | $(20.62) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Q1 2022 saw $15.2 million cash used in operations and $25.5 million in investing activities, contrasting with Q1 2021's $87.5 million financing inflow Cash Flow Summary (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(15,200) | $(5,137) | | Net cash used in investing activities | $(25,498) | $(71) | | Net cash provided by financing activities | $17 | $87,489 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's clinical-stage biotech focus, $133.3 million in funds sufficient for 12 months, and key license agreements - Aura Biosciences is a clinical-stage biotechnology company developing its Virus-Like Drug Conjugates (VDCs) platform, with its first candidate, AU-011, targeting primary choroidal melanoma and other cancers[31](index=31&type=chunk) - As of March 31, 2022, the company had **$133.3 million** in cash, cash equivalents, and marketable securities, expected to be sufficient for at least 12 months from the financial statement issuance date[35](index=35&type=chunk)[36](index=36&type=chunk) Stock-Based Compensation Expense (in thousands) | Category | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | Research and development | $555 | $44 | | General and administrative | $1,039 | $141 | | **Total** | **$1,594** | **$185** | - The company has entered into multiple key license agreements for its core technology with entities including LI-COR, Life Technologies, National Institute of Health (NIH), and Clearside, involving potential future milestone and royalty payments[85](index=85&type=chunk)[86](index=86&type=chunk)[97](index=97&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2022's $12.8 million net loss, driven by R&D and G&A, and confirms $133.3 million cash funds operations into 2024 - The company is a clinical-stage biotech focused on its lead candidate AU-011 for choroidal melanoma, with plans to initiate a pivotal trial in the second half of 2022 and expand into other indications like non-muscle invasive bladder cancer (NMIBC)[109](index=109&type=chunk) - The company has incurred significant operating losses since inception and expects them to continue, with a **net loss of $12.8 million** for Q1 2022 and an accumulated deficit of **$165.0 million** as of March 31, 2022[111](index=111&type=chunk) - With **$133.3 million** in cash, cash equivalents, and marketable securities as of March 31, 2022, management believes it has sufficient capital to fund operations into 2024[116](index=116&type=chunk)[142](index=142&type=chunk) Comparison of Results of Operations (in thousands) | Line Item | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | Research and development | $8,276 | $4,185 | | General and administrative | $4,535 | $1,742 | | **Net loss** | **$(12,835)** | **$(5,927)** | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=28&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Aura Biosciences is not required to provide information for this item - The company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item[154](index=154&type=chunk) [Item 4. Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of March 31, 2022, with no material changes to internal controls - Based on an evaluation as of the end of the period, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective[156](index=156&type=chunk) - There were no changes in the company's internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting[157](index=157&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=29&type=section&id=Item%201.%20Legal%20Proceedings) As of March 31, 2022, the company is not a party to any material legal proceedings - The company is not currently party to any claim or litigation that would be reasonably expected to have a material adverse effect on its business[159](index=159&type=chunk) [Item 1A. Risk Factors](index=29&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks including financial losses, dependence on AU-011, reliance on third parties, and regulatory hurdles - **Financial Risk:** The company has a history of significant net losses (**$12.8 million** in Q1 2022) and expects to incur losses for the foreseeable future, requiring substantial additional capital[162](index=162&type=chunk) - **Product Dependency Risk:** The company's business is heavily dependent on the success of AU-011, its only product candidate to date[179](index=179&type=chunk) - **Third-Party Reliance Risk:** The company relies on third-party CMOs for manufacturing and CROs for clinical trials, which increases risks related to supply, quality control, and trial execution[237](index=237&type=chunk)[241](index=241&type=chunk) - **Regulatory and Commercialization Risk:** The company faces significant hurdles in obtaining regulatory approval for its novel biologic-device combination product and achieving market acceptance if approved[183](index=183&type=chunk)[193](index=193&type=chunk)[251](index=251&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=75&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales occurred; IPO net proceeds of $78.3 million remain consistent with planned use - The company completed its IPO on November 2, 2021, with net proceeds of approximately **$78.3 million** after deducting discounts, commissions, and expenses[400](index=400&type=chunk) - There has been no material change in the planned use of proceeds from the IPO as disclosed in the prospectus[402](index=402&type=chunk) [Item 3. Defaults Upon Senior Securities](index=75&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) Not applicable - Not applicable[403](index=403&type=chunk) [Item 4. Mine Safety Disclosures](index=75&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Not applicable - Not applicable[403](index=403&type=chunk) [Item 5. Other Information](index=75&type=section&id=Item%205.%20Other%20Information) None - None[403](index=403&type=chunk) [Item 6. Exhibits](index=76&type=section&id=Item%206.%20Exhibits) This section lists exhibits, including corporate governance documents and SOX certifications by key officers - The report includes certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[405](index=405&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-----------------------------------------------------------------------------------------|------------------------------------------| | | | | Commission File Number: | 001- ...